RGLS

Regulus Therapeutics Inc

Add to Watchlist

Advanced Chart

0.000

-8.16(-100.000%)1D

Overview
Forecast
Valuation
Earnings

High

Open

VWAP

Vol

Mkt Cap

132.57M

Low

Amount

EV/EBITDA(TTM)

Total Shares

65.47M

499.59M

EV/OCF(TTM)

P/S(TTM)

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.233

+16.67%

-0.213

+1.59%

-0.180

+5.88%

Estimates Revision

The market is revising No Change the revenue expectations for Regulus Therapeutics Inc. (RGLS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 305.97%.

EPS Estimates for FY2025

Revise Downward

-35.79%

In Past 3 Month

Stock Price

Go Up

+305.97%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast RGLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGLS is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

5 Hold

0 Sell

Hold

Current: 0

Low

7.00

Averages

8.50

High

11.00

Current: 0

Low

7.00

Averages

8.50

High

11.00

Wells Fargo

Yanan Zhu

Hold

Buy

Upgrades

$3 → $6

2025-03-27

Reason

Wells Fargo

Yanan Zhu

Price Target

$3 → $6

2025-03-27

Upgrades

Hold

Buy

Reason

Wells Fargo upgraded Regulus to Overweight from Equal Weight with a price target of $6, up from $3.

Canaccord Genuity

Whitney Ijem

Strong Buy

Maintains

$28

2025-03-17

Reason

Canaccord Genuity

Whitney Ijem

Price Target

$28

2025-03-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$10

2025-03-14

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$10

2025-03-14

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$10

2025-02-26

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$10

2025-02-26

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$10

2024-11-11

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$10

2024-11-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$10

2024-10-30

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$10

2024-10-30

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Regulus Therapeutics Inc (RGLS.O) is -9.26, compared to its 5-year average forward P/E of -1.92. For a more detailed relative valuation and DCF analysis to assess Regulus Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.92

Current PE

-9.26

Overvalued PE

-0.44

Undervalued PE

-3.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.23

Current EV/EBITDA

-8.23

Overvalued EV/EBITDA

1.08

Undervalued EV/EBITDA

-1.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

611.40

Current PS

0.00

Overvalued PS

2280.51

Undervalued PS

-1057.70

Financials

Annual

Quarterly

FY2025Q1

N/A

Total Revenue

FY2025Q1

YoY :

+19.40%

-10.54M

Operating Profit

FY2025Q1

YoY :

+13.76%

-9.63M

Net Income after Tax

FY2025Q1

YoY :

-48.28%

-0.15

EPS - Diluted

FY2025Q1

YoY :

+18.30%

-10.61M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

310.7K

USD

0-12

Months

0.0

USD

Bought

0-3

95.8K

USD

Months

3-6

0.0

USD

Months

6-9

75.0K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 434.9% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.3M

Volume

6-9

Months

430.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.7M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

310.7K

USD

0-12

Months

0.0

USD

Bought

0-3

95.8K

USD

Months

3-6

0.0

USD

Months

6-9

75.0K

USD

Months

0-12

0.0

USD

Months

RGLS News & Events

Events Timeline

2025-06-25 (ET)

2025-06-25

09:20:07

Novartis completes acquisition of Regulus Therapeutics

2025-06-25

06:08:56

Novartis announces expiration of Regulus Therapeutics tender offer

2025-06-23 (ET)

2025-06-23

06:27:02

Novartis announces expiration of HSR waiting period of Regulus offer

News

7.0

05-15Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders

8.5

05-15Globenewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq - SSBK)

9.5

05-08PRnewswire

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates